Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Taking the fight against the dreaded Nipha disease to a new level, researchers at Pune-based Indian Institute of Science Education and Research (IISER) have developed drug targets for the virus that causes the disease, using the molecular modeling approach.

    Nipah virus outbreaks have very high mortality rates. They are over 70 per cent in Southeast Asia. The virus spreads via bodily secretions of bats, pigs and infected individuals. It was first detected in human population in 1998 in Malaysia, It made its way into Indian subcontinent with outbreaks in Bangladesh and India a few years later.

    (adsbygoogle = window.adsbygoogle || []).push({});
  • Biocon Ltd an innovation-led global biopharmaceuticals company and Equillium Inc, a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, announced that they have expanded their collaboration and license agreement for itolizumab to grant Equillium exclusive rights for developing and commercializing itolizumab in Australia and New Zealand.

    Equillium had originally secured exclusive rights to develop and commercialize Biocon’s novel biologic, itolizumab, for the U.S. and Canada markets, in May 2017.

  • A treatment for neurological disorder, Huntington's disease, could be in the offing. A group of researchers from the Indian Institute of Technology-Indore have identified three chemical molecules that could potentiually be used to arrest its progression.

  • Under Ayushman Bharat, Government has done addition to the primary health team at the Sub Health Centres and Health & Wellness Centres (HWC), would be the Mid-level Health Provider (MLHP) who would be a Community Health Officer. And National Health Mission (NHM) confirmed that Pharmacists are not eligible for same.

  • A common concern with oral vitamin B12 therapy is absorption especially in people suffering from anemia and gastrointestinal diseases. Researchers at the Council of Scientific and Industrial Research-Central Institute of Medicinal and Aromatic Plants (CSIR-CIMAP) have identified a plant extract that has shown potential in enhancing absorption of vitamin B12 through in vitro and in vivo bioassays.

Subscribe to Pharma News